论文部分内容阅读
Objective: Brain-specific angiogenesis inhibitor 1 (BAI1) was initially described in 1997,and there have since been a number of studies on its expression in different types of cancer.The aim of the present study was to investigate the expression levels of BAI1 in bladder transitional cell carcinoma (BTCC) at different stages and the mechanismby which it inhibits tumor endothelial cell proliferation.